Kerri A. Schoedel, Ph.D. - Publications

2004 University of Toronto, Toronto, ON, Canada 
Addiction, Drug Metabolism

35 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Schoedel KA, Szeto I, Setnik B, Sellers EM, Levy-Cooperman N, Mills C, Etges T, Sommerville K. Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial. Epilepsy & Behavior : E&B. 88: 162-171. PMID 30286443 DOI: 10.1016/j.yebeh.2018.07.027  0.6
2017 Schoedel KA, Stockis A, Sellers EM. Human abuse potential of brivaracetam in healthy recreational central nervous system depressant users. Epilepsy & Behavior : E&B. PMID 29153631 DOI: 10.1016/j.yebeh.2017.09.008  0.6
2017 Schoedel KA, Andreas JO, Doty P, Eckhardt K, Sellers EM. Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Crossover Study Evaluating the Abuse Potential of the Antiepileptic Drug Lacosamide in Healthy Recreational Drug Users. Journal of Clinical Psychopharmacology. PMID 28926353 DOI: 10.1097/JCP.0000000000000780  0.6
2016 Levy-Cooperman N, Schoedel KA, Chakraborty B, Blum D, Cheng H. Abuse liability assessment of eslicarbazepine acetate in healthy male and female recreational sedative users: A Phase I randomized controlled trial. Epilepsy & Behavior : E&B. 61: 63-71. PMID 27315134 DOI: 10.1016/j.yebeh.2016.05.010  0.96
2016 Schoedel KA, Sun H, Sellers EM, Faulknor J, Levy-Cooperman N, Li X, Kennedy WP, Cha JH, Lewis NM, Liu W, Bondiskey P, McCrea JB, Panebianco DL, Troyer MD, Wagner JA. Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover Study. Journal of Clinical Psychopharmacology. PMID 27253658 DOI: 10.1097/JCP.0000000000000516  0.96
2016 Koblan KS, Hopkins SC, Sarma K, Gallina N, Jin F, Levy-Cooperman N, Schoedel KA, Loebel A. Assessment of human abuse potential of dasotraline compared to methylphenidate and placebo in recreational stimulant users Drug and Alcohol Dependence. 159: 26-34. DOI: 10.1016/j.drugalcdep.2015.10.029  0.96
2015 Shram MJ, Cohen-Barak O, Chakraborty B, Bassan M, Schoedel KA, Hallak H, Eyal E, Weiss S, Gilgun Y, Sellers EM, Faulknor J, Spiegelstein O. Assessment of Pharmacokinetic and Pharmacodynamic Interactions Between Albumin-Fused Mutated Butyrylcholinesterase and Intravenously Administered Cocaine in Recreational Cocaine Users. Journal of Clinical Psychopharmacology. 35: 396-405. PMID 26082975 DOI: 10.1097/JCP.0000000000000347  0.96
2015 Mansbach RS, Schoedel KA. Incorporation of Abuse Potential Assessment into the Development of New Prescription Drugs Pharmaceutical Medicine. 29: 141-153. DOI: 10.1007/s40290-015-0095-5  0.96
2014 Schoedel KA, Morrow SA, Sellers EM. Evaluating the safety and efficacy of dextromethorphan/quinidine in the treatment of pseudobulbar affect. Neuropsychiatric Disease and Treatment. 10: 1161-74. PMID 25061302 DOI: 10.2147/NDT.S30713  0.96
2014 Romach MK, Schoedel KA, Sellers EM. Human abuse liability evaluation of CNS stimulant drugs. Neuropharmacology. 87: 81-90. PMID 24793872 DOI: 10.1016/j.neuropharm.2014.04.014  0.96
2014 Cruz HG, Hoever P, Chakraborty B, Schoedel K, Sellers EM, Dingemanse J. Assessment of the abuse liability of a dual orexin receptor antagonist: a crossover study of almorexant and zolpidem in recreational drug users. Cns Drugs. 28: 361-72. PMID 24627301 DOI: 10.1007/s40263-014-0150-x  0.96
2014 Sellers EM, Shram MJ, Schoedel KA. The US FDA Draft Guidance for Developing Abuse-Deterrent Opioid Analgesics: 2014 and Beyond Pharmaceutical Medicine. 28: 317-327. DOI: 10.1007/s40290-014-0067-1  0.96
2013 Sellers EM, Schoedel K, Bartlett C, Romach M, Russo EB, Stott CG, Wright S, White L, Duncombe P, Chen CF. A Multiple-Dose, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group QT/QTc Study to Evaluate the Electrophysiologic Effects of THC/CBD Spray. Clinical Pharmacology in Drug Development. 2: 285-94. PMID 27121791 DOI: 10.1002/cpdd.36  0.96
2013 Romach MK, Schoedel KA, Sellers EM. Update on tamper-resistant drug formulations. Drug and Alcohol Dependence. 130: 13-23. PMID 23415386 DOI: 10.1016/j.drugalcdep.2012.12.028  0.96
2012 Schoedel KA, Rolleri RL, Faulknor JY, Pixton GC, Chen N, Bass A, Sommerville KW, Sellers E. Assessing subjective and physiologic effects following intranasal administration of a new formulation of immediate release oxycodone HCl (Oxectaâ„¢) tablets in nondependent recreational opioid users. Journal of Opioid Management. 8: 315-27. PMID 23247908 DOI: 10.5055/jom.2012.0131  0.96
2012 Schoedel KA, Addy C, Chakraborty B, Rosko K, Dunbar S, Maes A, Chen N, Stoch SA, Wagner J, Chodakewitz J, Sellers EM. Human abuse potential and cognitive effects of taranabant, a cannabinoid 1 receptor inverse agonist: a randomized, double-blind, placebo- and active-controlled, crossover study in recreational polydrug users. Journal of Clinical Psychopharmacology. 32: 492-502. PMID 22722508 DOI: 10.1097/JCP.0b013e31825d380d  0.96
2012 Schoedel KA, Harrison SJ. Subjective and physiological effects of oromucosal sprays containing cannabinoids (nabiximols): potentials and limitations for psychosis research. Current Pharmaceutical Design. 18: 5008-14. PMID 22716155  0.96
2012 Pope LE, Schoedel KA, Bartlett C, Sellers EM. A study of potential pharmacokinetic and pharmacodynamic interactions between dextromethorphan/quinidine and memantine in healthy volunteers. Clinical Drug Investigation. 32: e1-15. PMID 22712629 DOI: 10.2165/11633850-000000000-00000  0.96
2012 Schoedel KA, Pope LE, Sellers EM. Randomized open-label drug-drug interaction trial of dextromethorphan/quinidine and paroxetine in healthy volunteers. Clinical Drug Investigation. 32: 157-69. PMID 22283559 DOI: 10.2165/11599870-000000000-00000  0.96
2011 McMorn S, Schoedel KA, Sellers EM. Effects of low-dose opioids on cognitive dysfunction. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4342-3; author reply. PMID 21969492 DOI: 10.1200/JCO.2011.38.2309  0.96
2011 Schoedel KA, McMorn S, Chakraborty B, Potts SL, Zerbe K, Sellers EM. Positive and negative subjective effects of extended-release oxymorphone versus controlled-release oxycodone in recreational opioid users. Journal of Opioid Management. 7: 179-92. PMID 21823549 DOI: 10.5055/jom.2011.0061  0.96
2011 Schoedel KA, Chen N, Hilliard A, White L, Stott C, Russo E, Wright S, Guy G, Romach MK, Sellers EM. A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use. Human Psychopharmacology. 26: 224-36. PMID 21671456 DOI: 10.1002/hup.1196  0.96
2011 Shram MJ, Schoedel KA, Bartlett C, Shazer RL, Anderson CM, Sellers EM. Evaluation of the abuse potential of lorcaserin, a serotonin 2C (5-HT2C) receptor agonist, in recreational polydrug users. Clinical Pharmacology and Therapeutics. 89: 683-92. PMID 21412231 DOI: 10.1038/clpt.2011.20  0.96
2010 Schoedel KA, McMorn S, Chakraborty B, Zerbe K, Sellers EM. Reduced cognitive and psychomotor impairment with extended-release oxymorphone versus controlled-release oxycodone. Pain Physician. 13: 561-73. PMID 21102969  0.96
2010 Mansbach RS, Schoedel KA, Kittrelle JP, Sellers EM. The role of adverse events and related safety data in the pre-market evaluation of drug abuse potential. Drug and Alcohol Dependence. 112: 173-7. PMID 20817417 DOI: 10.1016/j.drugalcdep.2010.07.001  0.96
2010 Schoedel KA, Meier D, Chakraborty B, Manniche PM, Sellers EM. Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users. Clinical Pharmacology and Therapeutics. 88: 69-78. PMID 20520602 DOI: 10.1038/clpt.2010.67  0.96
2008 Schoedel KA, Sellers EM. Assessing abuse liability during drug development: changing standards and expectations. Clinical Pharmacology and Therapeutics. 83: 622-6. PMID 18212799 DOI: 10.1038/sj.clpt.6100492  0.96
2007 Wall TL, Schoedel K, Ring HZ, Luczak SE, Katsuyoshi DM, Tyndale RF. Differences in pharmacogenetics of nicotine and alcohol metabolism: review and recommendations for future research. Nicotine & Tobacco Research : Official Journal of the Society For Research On Nicotine and Tobacco. 9: S459-74. PMID 17978975 DOI: 10.1080/14622200701587045  0.96
2007 Parasrampuria DA, Schoedel KA, Schuller R, Gu J, Ciccone P, Silber SA, Sellers EM. Assessment of pharmacokinetics and pharmacodynamic effects related to abuse potential of a unique oral osmotic-controlled extended-release methylphenidate formulation in humans. Journal of Clinical Pharmacology. 47: 1476-88. PMID 17962423 DOI: 10.1177/0091270007308615  0.96
2007 Parasrampuria DA, Schoedel KA, Schuller R, Silber SA, Ciccone PE, Gu J, Sellers EM. Do formulation differences alter abuse liability of methylphenidate? A placebo-controlled, randomized, double-blind, crossover study in recreational drug users. Journal of Clinical Psychopharmacology. 27: 459-67. PMID 17873677 DOI: 10.1097/jcp.0b013e3181515205  0.96
2004 Schoedel KA, Hoffmann EB, Rao Y, Sellers EM, Tyndale RF. Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics. 14: 615-26. PMID 15475735 DOI: 10.1097/00008571-200409000-00006  0.96
2004 Dempsey D, Tutka P, Jacob P, Allen F, Schoedel K, Tyndale RF, Benowitz NL. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clinical Pharmacology and Therapeutics. 76: 64-72. PMID 15229465 DOI: 10.1016/j.clpt.2004.02.011  0.96
2003 Schoedel KA, Tyndale RF. Induction of nicotine-metabolizing CYP2B1 by ethanol and ethanol-metabolizing CYP2E1 by nicotine: summary and implications. Biochimica Et Biophysica Acta. 1619: 283-90. PMID 12573488 DOI: 10.1016/S0304-4165(02)00487-7  0.96
2003 Schoedel KA, Sellers EM, Palmour R, Tyndale RF. Down-regulation of hepatic nicotine metabolism and a CYP2A6-like enzyme in African green monkeys after long-term nicotine administration. Molecular Pharmacology. 63: 96-104. PMID 12488541 DOI: 10.1124/mol.63.1.96  0.96
2001 Schoedel KA, Sellers EM, Tyndale RF. Induction of CYP2B1/2 and nicotine metabolism by ethanol in rat liver but not rat brain. Biochemical Pharmacology. 62: 1025-36. PMID 11597571 DOI: 10.1016/S0006-2952(01)00744-4  0.96
Show low-probability matches.